Pamela A. Hershberger

Roswell Park Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors”.

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

ChemRxiv(2023)10.26434/chemrxiv-2023-cs3xn-v2

N/A

0.208DataRank · unranked

3 citations

Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D. Pham, Ilse K. Schaeffner +15 more

Noninvasive Monitoring of Radiation-Induced Salivary Gland Vascular Injury

Journal of Dental Research(2022)10.1177/00220345221138533

N/A

0DataRank · unranked

9 citations

Laurie J. Rich, Vui King Vincent–Chong, Celia DeJohn, Mihai Merzianu, Pamela A. Hershberger +3 more

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)

ChemRxiv(2022)10.26434/chemrxiv-2022-5m8h5-v2

N/A

0DataRank · unranked

3 citations

Tyler S. Beyett, Tatiana Shaurova, Calvin Pham, Florian Wittlinger, Ilse K. Schaeffner +6 more

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)

ChemRxiv(2022)10.26434/chemrxiv-2022-5m8h5

N/A

0DataRank · unranked

0 citations

Tyler S. Beyett, Tatiana Shaurova, Calvin Pham, Florian Wittlinger, Ilse K. Schaeffner +6 more

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer

Cancer Communications(2023)10.1002/cac2.12401

N/A

0DataRank · unranked

6 citations

Lingyue Yan, Yafei Su, Laurie J. Rich, Vui King Vincent–Chong, Hannah Calkins +6 more

Examining molecular factors of inactive versus active bivalent EGFR inhibitors: A missing link in fragment-based drug design.

ChemRxiv(2023)10.26434/chemrxiv-2023-cs3xn

N/A

0DataRank · unranked

3 citations

Blessing C. Ogboo, Calvin D. Pham, Ilse K. Schaeffner, Surbhi P. Chitnis, Tahereh Damghani +12 more

The origin of potency and mutant-selective inhibition by bivalent ATP-allosteric EGFR inhibitors

ChemRxiv(2023)10.26434/chemrxiv-2023-zzfc3

N/A

0DataRank · unranked

2 citations

Surbhi P. Chitnis, Calvin D Pham, Tahereh Damghani, Ilse K. Schaeffner, Matthew Q. Deng +13 more

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

Research Square(2023)10.21203/rs.3.rs-3286949/v1

N/A

0DataRank · unranked

0 citations

Florian Wittlinger, Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin Pham +15 more

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

Communications Chemistry(2024)10.1038/s42004-024-01108-3

N/A

0DataRank · unranked

24 citations

Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D. Pham, Ilse K. Schaeffner +15 more

Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance

Cancers(2020)10.3390/cancers12030675

N/A

0DataRank · unranked

20 citations

Grace K. Dy, Sebastiano Battaglia, Alan D. Hutson, Letian Zhang, Yunkai Zhang +6 more

Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent “Type V” Kinase Inhibitors

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.4c02311

N/A

0DataRank · unranked

8 citations

Surbhi P. Chitnis, Calvin D. Pham, Tahereh Damghani, Kishan B. Patel, Mareike Möllers +17 more